Submitting an IND application to the FDA is a critical regulatory step for advancing clinical trials. Positive news about progressing to a Phase IIb trial could increase investor confidence in Can-Fite BioPharma's pipeline, potentially leading to a short-term positive impact on the stock price. The focus on NASH, a significant and growing market, underscores the potential value of Namodenoson if successful.